Scientific Opinion on the modification of the authorisation of a health claim related to water-soluble tomato concentrate and helps to maintain a healthy blood flow and benefits circulation pursuant to Article 13(5) of Regulation (EC) No 1924/2006 following a request in accordance with Article 19 of the Regulation (EC) No 1924/2006 EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA)

被引：2

作者：

Agostoni, Carlo ^{[1
]}

Bresson, Jean-Louis ^{[1
]}

Fairweather-Tait, Susan ^{[1
]}

Flynn, Albert ^{[1
]}

Golly, Ines ^{[1
]}

Korhonen, Hannu ^{[1
]}

Lagiou, Pagona ^{[1
]}

Lovik, Martinus ^{[1
]}

Marchelli, Rosangela ^{[1
]}

Martin, Ambroise ^{[1
]}

Moseley, Bevan ^{[1
]}

Neuhaeuser-Berthold, Monika ^{[1
]}

Przyrembel, Hildegard ^{[1
]}

Salminen, Seppo ^{[1
]}

Sanz, Yolanda ^{[1
]}

Strain, Sean ^{[1
]}

Strobel, Stephan ^{[1
]}

Tetens, Inge ^{[1
]}

Tome, Daniel ^{[1
]}

van Loveren, Hendrik ^{[1
]}

Verhagen, Hans ^{[1
]}

机构：

[1] EFSA, Parma, Italy

来源：

EFSA JOURNAL | 2010年 / 8卷 / 07期

关键词：

Water soluble tomato concentrate; platelet aggregation; clotting time; adults; conditions of use; health claims;

D O I：

10.2903/j.efsa.2010.1689

中图分类号：

TS2 [食品工业];

学科分类号：

0832 ;

摘要：

Following an application from Provexis Natural Products Limited submitted pursuant to Article 19 of Regulation (EC) No 1924/2006 via the Competent Authority of United Kingdom, the Panel on Dietetic Products, Nutrition and Allergies (NDA) was asked to deliver an opinion on a request for modification of the authorisation of a health claim related to water-soluble tomato concentrate and platelet aggregation. The modification concerns an extension of the authorised health claim to additional proposed conditions of use for powdered single-serve sachets, tablets, and capsules. The scope of the application was proposed to fall under a health claim based on newly developed scientific evidence and/or including a request for the protection of proprietary data. The Panel considers that the food constituents, water-soluble tomato concentrate I and II (i.e., in powder sachets, tablets and capsules), which are the subject of the claim are sufficiently characterised. The results of one unpublished study showed that the three water-soluble tomato concentrate formulations reduced platelet aggregation as compared to the corresponding control and baseline values, with no significant differences between the three formulations. The Panel concludes that a cause and effect relationship has been established between the consumption of water-soluble tomato concentrate I and II (corresponding to the specifications provided by the applicant) and a reduction in platelet aggregation under the new conditions of use proposed by the applicant (i.e., consumed as powder, tablets or capsules). (C) European Food Safety Authority, 2010

引用

页数：9

共 2 条

[1]

Scientific Opinion of the Panel on Dietetic Products, Nutrition and Allergies (NDA). Scientific substantiation of a health claim related to water-soluble tomato concentrate (WSTC I and II) and platelet aggregation pursuant to Article 13(5) of Regulation (EC) No 1924/2006, The EFSA Journal, 1101, pp. 1-15, (2009)

[2]

A randomised, controlled and double-blinded crossover study to compare the antiplatelet effects of three different formats of WSTC in healthy humans, (2007)

← 1 →